-
Company News For Dec 13, 2010 - Corporate Summary
Monday, December 13, 2010 - 10:33am | 639• Thermo Fisher (NYSE:TMO) said it would purchase Dionex (NASDAQ:DNEX), a manufacturer of chemical analysis equipment, for $118.50 per share, or $2.1 billion • According to this weekend's Barron's, Mattel (NASDAQ:MAT) shares offer good value, with potential for 20% appreciation over the next year...
-
Company News For Dec 13, 2010 - Corporate Summary
Monday, December 13, 2010 - 10:13am | 639• Thermo Fisher (NYSE:TMO) said it would purchase Dionex (NASDAQ:DNEX), a manufacturer of chemical analysis equipment, for $118.50 per share, or $2.1 billion • According to this weekend's Barron's, Mattel (NASDAQ:MAT) shares offer good value, with potential for 20% appreciation over the next year...
-
Dionex Jumps 20% on Thermo Fisher Deal (DNEX, TMO)
Monday, December 13, 2010 - 10:10am | 121Shares of Dionex Corporation (NASDAQ: DNEX) are trading higher this morning by 19.94%, at $117.75, after Thermo Fisher (NYSE: TMO) agreed to buy the company for $2.1 billion. Under the deal, Thermo Fisher will begin a tender offer to buy Dionex shares for $118.50 each, a 21% premium to Dionex's...
-
Positive Data From Nektar Therapeutics
Monday, December 13, 2010 - 9:51am | 154Hapoalim Securities has published a research report on Nektar Therapeutics (NASDAQ: NKTR) after the company announced positive news from the full Phase 2 trial of NKTR-102. In the report, Hapoalim writes "Nektar announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-...
-
J.P. Morgan Maintains OW Rating On Nektar Therapeutics
Monday, December 13, 2010 - 9:38am | 71J.P. Morgan reports that over the weekend, Nektar Therapeutics (NASDAQ: NKTR) presented promising Ph2 data for NKTR-102 in second line metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium (SABCS) wherein the objective response rate improved since this summer's topline update (...
-
Benzinga's Top Pre-Market NASDAQ Losers (NKTR, PWAV, HBAN, DELL)
Monday, December 13, 2010 - 9:26am | 130Nektar Therapeutics (NASDAQ: NKTR) dipped 3.98% to $13.50 in the pre-market session. NKTR's trailing-twelve-month ROE is -21.62%. Powerwave Technologies Inc (NASDAQ: PWAV) lost 3.70% to $2.60 in the pre-market session. PWAV's trailing-twelve-month profit margin is -0.97%. Huntington Bancshares...
-
Nektar Therapeutics Plunging 9% In Pre-Market
Monday, December 13, 2010 - 9:25am | 49Nektar Therapeutics (NASDAQ: NKTR) is dropping 9% in pre-market trading. Volume is particularly thin this morning. It's trading down $1.26 to $12.80, a loss of 8.96%. Nektar Therapeutics focuses on developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate...
-
Piper Jaffray Initiates Sequenom Coverage With An OW Rating And $8 PT
Monday, December 13, 2010 - 9:00am | 30Piper Jaffray is initiating coverage of Sequenom, Inc. (NASDAQ: SQNM) with an Overweight rating and a $8 price target. Sequenom closed Friday at $6.47.
-
Enzo Biochem Reports Q1 Loss
Monday, December 13, 2010 - 8:29am | 62Enzo Biochem Inc (NYSE: ENZ) reports its Q1 loss at $0.03 per share, versus the expected loss of $0.06 per share. ENZ reports its Q1 revenue at $25.7 million, versus the consensus of $26.09 million. ENZ shares lost 1.63% to close at $4.84 on Friday. Read more from Benzinga's Company news.
-
Neutral on MannKind - Analyst Blog
Friday, December 10, 2010 - 5:03pm | 592We are maintaining our Neutral recommendation on MannKind Corporation (MNKD) with a target price of $7.50. MannKind is a Valencia, California-based biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diabetes, cancer and inflammatory...
-
Neutral on MannKind - Analyst Blog
Friday, December 10, 2010 - 4:45pm | 592We are maintaining our Neutral recommendation on MannKind Corporation (MNKD) with a target price of $7.50. MannKind is a Valencia, California-based biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diabetes, cancer and inflammatory...
-
Charles River Laboratories to Report Guidance
Friday, December 10, 2010 - 9:57am | 134Jefferies is out with its report on Charles River Laboratories (NYSE: CRL) as CRL is set to report guidance on December, 14. In a report to clients, Jefferies notes, "We have picked up some minor indications of improvement in toxicology. Authorizations are higher now than 1 year ago...more so on...
-
Exelixis Surging On Strong Volume
Thursday, December 9, 2010 - 3:33pm | 86Exelixis, Inc. (NASDAQ: EXEL) is up more than 7% on strong volume. There is no specific news on the name, although some are speculating on a buyout coming in the name, but that is an unfounded rumor with no basis. At last check, volume was over 1.9 million shares, whereas average daily volume for...
-
Goldman Sachs Maintains CRL Rating And PT Ahead Of Guidance Call
Thursday, December 9, 2010 - 10:45am | 39Goldman Sachs said today that it is maintaining its Charles River Laboratories (NYSE: CRL) estimates, price target, and Neutral rating ahead of Tuesday's 2011 guidance call. Charles River Laboratories currently trades at $33.91.
-
Caliper Life Sciences to Acquire Cambridge Research & Instrumentation for $20M
Thursday, December 9, 2010 - 10:34am | 97Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research & Instrumentation, Inc. for approximately $20.0 million, including net debt. CRi's patented preclinical and tissue-based multiplexed analysis...